Final Results of a Phase II Trial of Preoperative TAC (Docetaxel/Doxorubicin/Cyclophosphamide) in Stage III Breast Cancer

O’Regan, Ruth; Roenn, Jamie H. Von; Carlson, R. W.; Malik, Ummekalsoom; Sparano, Joseph A.; Staradub, Valerie L.; Khan, Seema A.; Jovanovic, Borko; Morrow, Monica; Gradishar, William J.

doi:10.3816/cbc.2005.n.019

Cited by 25 publications

(29 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Smaller studies using other highly active regimens have achieved similar results. Doxorubicin and docetaxel given for six cycles achieved a pathological complete response rate of 8% as did docetaxel, doxorubicin, and cyclophosphamide (22,23). This compares favorably with the 31% (clinical complete response), 10% (pathological complete response in breast), and 7% (pathological complete response in breast and nodes) rates seen in our study with four cycles of docetaxel and capecitabine.…”

Section: Discussionsupporting

confidence: 72%

A Phase II Trial of Neoadjuvant Docetaxel and Capecitabine for Locally Advanced Breast Cancer

Lebowitz¹,

Eng‐Wong²,

Swain³

et al. 2004

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 72%

A Phase II Trial of Neoadjuvant Docetaxel and Capecitabine for Locally Advanced Breast Cancer

Lebowitz¹,

Eng‐Wong²,

Swain³

et al. 2004

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Both the ORR (88% versus 78%) and the pCR rate (8% versus 12%) were comparable for AT and for AC, respectively. A phase II study demonstrated that a combination of docetaxel, doxorubicin and cyclophosphamide (TAC) conferred ORR of 81% and pCR of 8% [38]. This does not appear to improve upon the historical experience with AC neoadjuvant therapy or with the findings of docetaxel monotherapy reported in the present study.…”

Section: Safetycontrasting

confidence: 79%

Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer

et al. 2005

View full text Add to dashboard Cite

Background: To evaluate clinical and pathologic response to neoadjuvant docetaxel therapy in patients with stage III breast cancer. Patients and methods: Forty-five patients were planned to receive four cycles of docetaxel 100 mg/m 2 every 3 weeks, followed by surgery, four cycles of doxorubicin 60 mg/m 2 and cyclophosphamide 600 mg/m 2 (AC) every 3 weeks, radiation therapy (RT), and tamoxifen when indicated.Results: After four cycles of neoadjuvant docetaxel, the clinical response rate within the breast was 59% (95% CI 42% to 73%) and overall (breast and axilla) was 49% (95% CI 38% to 72%) in the intention-to-treat (ITT) population. At the time of surgery, 10% (n = 4) of patients had a pathologic complete response (pCR) in the breast, 27% (n = 11) had a pCR within the axillary lymph nodes, and 7% (n = 3) had a pCR in the breast and axilla (95% CI 2% to 21%). An additional 5% (n = 2) had minimal residual invasive tumor (<5 mm). The 5-year overall survival rate was 80%. The percentage of patients with grade 3/4 neutropenia was similar during docetaxel (93%) and AC (86%), while a greater percentage of patients had febrile neutropenia during docetaxel treatment (27%) compared with AC treatment (7%). Conclusions: Neoadjuvant docetaxel followed by surgery, adjuvant AC, hormonal therapy where indicated, and RT is an active regimen for patients with stage III breast cancer.

show abstract

“…Although the addition of taxanes induced an increase in the pCR rate [30] in comparison with standard anthracycline-based regimens, its impact, particularly in sequence regimens, on the outcome in stage III B is unclear, since few series have examined this group of patients independently from those with other LABC (as T3 or any T, N2–3). With the TAC regimen, von Minckwitz et al [42] and O’Regan et al [43] showed pCR rates of only 6.7 and 10%, respectively, in the subgroup of patients with stage III B disease, not greater than with ‘old standard’ regimens [5, 7]. No pCRs were seen with the TEC regimen (docetaxel, epirubicin, cyclophosphamide) for 6 cycles in stage IIIB, as reported by Burdette-Radoux et al [44].…”

Section: Discussionmentioning

confidence: 99%

Dose-Dense Primary Chemotherapy, as Part of Multidisciplinary Treatment, for Inoperable Stage III B Breast Cancer – Long-Term Results of a Phase II Trial

Massidda¹,

Atzori²,

Scanu³

et al. 2007

Oncology

View full text Add to dashboard Cite

Background: Primary chemotherapy as part of multidisciplinary approach is the established treatment for inoperable stage III B breast cancer. The primary endpoints were conversion to operable disease and feasibility of conservative surgery (breast-conserving therapy: BCT); secondary were clinical and pathological complete response rate, local and distant control and safety of the primary regimen. Methods: Between 1998 and 2001, 40 inoperable breast cancer patients ≤60 years, 72% T4abc and 28% T4d, received 6 cycles of primary PEV dose-dense regimen: cisplatin 50 mg/m², epirubicin 100 mg/m² and vinorelbine 25 mg/m², i.v. (q 14). Modified radical mastectomy (MRM) or BCT was performed, followed by adjuvant chemotherapy, radiotherapy and hormone therapy. Results: All patients were converted to operable disease, and BCT was feasible in 24% of T4abc patients. After a median follow-up of 84 months (range 58–96), local and distant relapses were 7.5% (0% in BCT ) and 25% (25% in BCT), respectively. Clinical response was 80% (clinical complete response [cCR]: 20%); pathological complete response (pCR) was 40% in breast, 50% in axilla (pLN0); 32% both in breast and axilla. Neutropenia (G4, 30%), leukopenia (G4, 25%), alopecia (G2, 100%), nausea and vomiting (G4, 20%) were the most common toxicities. Conclusions: The PEV dose-dense regimen seems to be highly effective in terms of resectability and pCR. Toxicity, mainly hematological, was acceptable. Successful BCT is feasible, in selected patients, without compromising local and distant control.

show abstract

Final Results of a Phase II Trial of Preoperative TAC (Docetaxel/Doxorubicin/Cyclophosphamide) in Stage III Breast Cancer

Cited by 25 publications

References 8 publications

A Phase II Trial of Neoadjuvant Docetaxel and Capecitabine for Locally Advanced Breast Cancer

A Phase II Trial of Neoadjuvant Docetaxel and Capecitabine for Locally Advanced Breast Cancer

Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer

Dose-Dense Primary Chemotherapy, as Part of Multidisciplinary Treatment, for Inoperable Stage III B Breast Cancer – Long-Term Results of a Phase II Trial

Contact Info

Product

Resources

About